Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited has announced the final approval from Macquarie University’s Human Research Ethics Committee to enroll the last three patients in an Open-Label Extension study of monepantel for Motor Neurone Disease. The study aims to assess long-term safety and therapeutic benefits, with patients having been treated for up to 19 months and showing no safety concerns. This development marks a significant step in the pursuit of a new therapy for MND/ALS, offering hope for extended treatment options in a market with limited effective treatments.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
